Company release, 22 March 2023 at 12 p.m. (EET)

Nightingale Health Plc ("Nightingale Health" or the "Company") published on 27 October 2022 its first consolidated financial statements prepared in accordance with IFRS for the financial year ended 30 June 2022. Before publishing the consolidated financial statements Nightingale Health provided comparative information on its consolidated statement of income, statement of financial position and key financials for the financial year ended 30 June 2021 and for the opening IFRS statement of financial position as at the transition date, 1 July 2020. The Company also announced that it will publish comparative IFRS information for the half-year periods ended on 31 December 2021 and 30 June 2022 before the publication of the H1/2022-2023 half-year report.

In this company release Nightingale Health publishes comparative IFRS information for the half-year periods ended on 31 December 2021 and 30 June 2022.

The financial information in this company release has not been audited.

Key financials for the half-year period 1 July 2021 - 31 December 2021

-   Revenue was EUR 1,272 thousand

-   EBITDA was EUR -4,128 thousand

-   Operating loss was EUR -5,907 thousand

-   Loss for the period was EUR -5,758 thousand

-   Earnings per share (EPS) amounted to EUR -0.1 (Series A shares and EMP shares) and EUR -0.1 (Series B shares)

-   Cash and cash equivalents at the end of the period totaled EUR 105,413 thousand

Key financials for the half-year period 1 January 2022 - 30 June 2022

-   Revenue was EUR 1,041 thousand

-   EBITDA was EUR -5,261 thousand

-   Operating loss was EUR -7,727 thousand

-   Loss for the period was EUR -10,332 thousand

-   Earnings per share (EPS) amounted to EUR -0.17 (Series A shares and EMP shares) and EUR -0.17 (Series B shares)

-   Cash and cash equivalents at the end of the period totaled EUR 95,279 thousand

Consolidated statement of income and comprehensive income 1 Jul 2021 - 31 Dec 2021*

EUR thousand FAS Total IFRS IFRS
1 Jul
2021 adjustments 1 Jul
- 2021
-
31
Dec 31
2021 Dec
2021
Revenue 1,322 -50 1,272
Other income 20 1 21
Materials and -404 - -404
services
Employee -1,139 -1,747 -2,887
benefits
Depreciation, -1,526 -252 -1,778
amortization,
and
impairment
losses
Other -3,050 944 -2,107
expenses
Share of -2 -22 -24
joint
venture's
result
Operating -4,780 -1,126 -5,907
profit (loss)
Finance 171 -117 54
income
Finance costs -453 -63 -515
Fair value - 537 537
change in
investment in
convertible
loan
Net finance -281 357 76
items
Profit (loss) -5,062 -769 -5,831
before tax
Income tax -1 73 72
expense
Profit (loss) -5,063 -696 -5,758
for the
period

Consolidated
statement of
comprehensive
income

Profit (loss) -5,063 -696 -5,758
for the
period
Other
comprehensive
income
Items that
may be
reclassified
subsequently
to profit or
loss
Foreign - -9 -9
operations -
foreign
currency
translation
differences,
net of tax
Other - -9 -9
comprehensive
income for
the period,
net of tax
Total -5,063 -705 -5,768
comprehensive
income for
the period

Consolidated statement of income and comprehensive income 1 Jan 2022 - 30 Jun 2022*

EUR thousand FAS FAS- Total IFRS IFRS
adjustments
1 Jan 2022 correction 1 Jan
-30 Jun 2022 -
2022
30 Jun
2022
Revenue 884 - 157 1,041
Other income 242 - - 242
Materials and services -633 - - -633
Employee benefits -1,845 - -1,767 -3,613
Depreciation, amortization, and -1,713 - -753 -2,466
impairment losses
Other expenses -3,262 - 963 -2,299
Share of joint venture's result 23 - -22 1
Operating profit (loss) -6,305 - -1,422 -7,727
Finance income 755 - -124 631
Finance costs -706 - 43 -663
Fair value change in investment in -4,103 588 910 -2,604
convertible loan
Net finance items -4,053 588 829 -2,636
Profit (loss) before tax -10,358 588 -593 -10,363

Income tax expense 45 - -14 31
Profit (loss) for the period -10,313 588 -607 -10,332

Consolidated statement of
comprehensive income

Profit (loss) for the period -10,313 588 -607 -10,332

Other comprehensive income
Items that may be reclassified
subsequently to profit or loss
Foreign operations - foreign - - 38 38
currency translation differences,
net of tax
Other comprehensive income for the - - 38 38
period, net of tax
Total comprehensive income for the -10,313 588 -569 -10,294
period

* A more detailed bridge calculation of the IFRS transition from the consolidated statement of income is presented in appendix A of this company release. The adjustments made are described in more detail in Note 2 Transition to IFRS of the consolidated financial statements of 1 July 2021-30 June 2022.

Consolidated statement of financial position 31 Dec 2021*

EUR thousand FAS Total IFRS adjustments IFRS

31 Dec 2021 31 Dec 2021
Assets
Non-current assets
Goodwill 710 -247 463
Intangible assets 15,692 -1,746 13,946
Property, plant and 1,460 1,580 3,041
equipment
Right-of-use assets - 5,061 5,061
Equity-accounted 53 48 101
investees
Investment in 3,649 420 4,068
convertible loan
Other assets 491 -185 307
Total non-current 22,056 4,930 26,987
assets

Current assets
Inventories 536 - 536
Trade and other 1,197 -11 1,186
receivables
Cash and cash 105,413 - 105,413
equivalents
Total current assets 107,147 -11 107,136
Total assets 129,203 4,920 134,123

Equity and
liabilities
Equity
Share capital 80 - 80
Reserve for invested 147,338 -5,010 142,327
unrestricted equity
Translation 3 -1 2
differences
Retained loss -27,097 4,854 -22,243
Total equity 120,324 -157 120,167
Liabilities
Non-current
liabilities
Loans and borrowings 2,288 689 2,978
Lease liabilities - 2,615 2,615
Total non-current 2,288 3,305 5,593
liabilities
Current liabilities
Loans and borrowings 1,711 354 2,065
Lease liabilities - 1,447 1,447
Advances received 1,701 - 1,701
Trade and other 3,179 -29 3,150
payables
Total current 6,591 1,772 8,363
liabilities
Total liabilities 8,879 5,077 13,956
Total equity and 129,203 4,920 134,123
liabilities

* A more detailed bridge calculation of the IFRS transition from the consolidated statement of financial position is presented in appendix B of this company release. The adjustments made are described in more detail in Note 2 Transition to IFRS of the consolidated financial statements of 1 July 2021-30 June 2022.

For further information, please contact:

CEO Teemu Suna

ir@nightingalehealth.com

Certified Adviser:

Oaklins Merasco Ltd, tel. +358 9 6129 670

Appendices

Nightingale Health Plc Company release IFRS comparative information, which includes:

Appendix A Consolidated statement of income and consolidated statement of comprehensive income 1Jul 2021 - 31 Dec 2021 and 1 Jan 2022 - 30 Jun 2022.

Appendix B Consolidated statement of financial position 31 Dec 2021

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it's also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.